The role of androgen and its related signals in PCOS

Ye, Wenting; Xie, Tingting; Song, Yonggui; Zhou, Lili

doi:10.1111/jcmm.16205

Cited by 97 publications

(71 citation statements)

References 108 publications

(192 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, irregular menses, hirsutism, anovulation, dyslipidemia, hypertension, insulin resistance, and polycystic ovaries when other etiologies are excluded [ 1 – 3 ]. There are 10–15% of reproductive-aged women affected with PCOS [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials

Chen

Huang

Zhang

et al. 2021

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Several clinical studies showed that statins were potential to treat polycystic ovary syndrome (PCOS). Through comprehensive search PubMed, EMBASE, the Web of Science, BIOSIS, the ClinialTrails.gov, and the Cochrane Library database up to 14 Feb 2020, we identified the randomized controlled trials about the treatment of statins on hyperandrogenism in PCOS women, and performed a systematic review and meta-analysis. The quality of the included studies was assessed by the Cochrane risk of bias tool and the Jadda score. Subgroup analysis and sensitivity analysis were conducted to analyze the pooled results. Nine trials included 682 PCOS patients were identified. Statins showed a significant potential to reduce testosterone (SMD = -0.47; 95% CI, − 0.76−− 0.18; P = 0.002) and dehydroepiandrosterone (SMD = -0.51; 95% CI, − 0.97−− 0.05; P = 0.03) levels, compared to the control treatments. The cutaneous symptoms hirsutism (SMD = -0.61; 95% CI, − 1.13−− 0.10; P = 0.02) and acne (SMD = -0.92; 95% CI, − 1.49−− 0.34; P = 0.002) were significantly improved by statins in PCOS women. Subgroup analysis showed that the two types of statins, and the different control treatments as well, presented no significantly different effect on testosterone and dehydroepiandrosterone. Sensitivity analysis confirmed the stability of the findings from the meta-analysis. In conclusion, statin treatment could significantly reduce androgen levels and improve cutaneous manifestations of hyperandrogenism of PCOS.

show abstract

Section: Introductionmentioning

confidence: 99%

“…There are 10–15% of reproductive-aged women affected with PCOS [ 4 ]. Up to 60–80% of women with PCOS appear hyperandrogenism [ 1 ]. Hyperandrogenism is a medical condition characterized by excessive levels of androgens in the periphery or systemically.…”

Section: Introductionmentioning

confidence: 99%

The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials

Chen

Huang

Zhang

et al. 2021

Reprod Biol Endocrinol

View full text Add to dashboard Cite

show abstract

“…Hyperandrogenemia is the main endocrine characteristic of PCOS. Hyperinsulinemia and IR are considered to be the main causes of hyperandrogenemia [ 35 , 36 ], while excessive androgen leads to increased levels of LH and FSH [ 37 ]. In PCOS, theca cells and granulosa cells overexpress mRNA encoding enzymes involved in steroidogenesis, including androgen receptor, CYP11, CYP17, and CYP19, and this can lead to disturbances in ovarian hormone synthesis.…”

Section: Discussionmentioning

confidence: 99%

The Effects of Salvia miltiorrhiza on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

Shen

Jin

Yaguang

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. As a traditional medicine, Salvia miltiorrhiza (S. miltiorrhiza) has been widely used in the treatment of many gynecological diseases, but the efficacy of S. miltiorrhiza in women with PCOS has not been assessed. The purpose of this systematic review and meta-analysis was to evaluate the effectiveness and safety of S. miltiorrhiza in women with PCOS. Methods. We conducted searches in PubMed, Embase, the Cochrane Library, the China National Knowledge Infrastructure, the Wanfang Database, the Chinese Scientific Journal Database, and the Chinese BioMedical database from inception to December 23, 2020, to identify studies that met the inclusion criteria. The quality of the evidence was estimated using the Cochrane Reviewer Handbook 5.0.0, and the meta-analysis was performed using RevMan 5.3.5 software. Results. Six randomized controlled trials (RCTs) involving 390 patients with PCOS were included. The studies suggested that S. miltiorrhiza extract combined with letrozole (LET) was more effective in improving pregnancy rate (RR: 2.60, 95% CI: 1.06 to 6.39, P = 0.04 ) compared to LET alone. S. miltiorrhiza extract was associated with decreased fasting blood glucose (MD: –0.25, 95% CI: –0.37 to –0.13, P < 0.0001 ), fasting insulin (MD: –1.16, 95% CI: –1.74 to –0.58, P < 0.0001 ), total cholesterol (TC) (MD: –0.58, 95% CI: –0.72 to –0.43, P < 0.00001 ), and triglycerides (TG) (MD: –0.31, 95% CI: –0.35 to –0.26, P < 0.00001 ) compared with placebo, but not with improvements in body mass index or waist-to-hip ratio (MD: –1.41, 95% CI: –4.81 to 2.00, P = 0.42 ; MD: –0.02, 95% CI: –0.05 to 0.01, P = 0.16 , respectively). There was a significant difference between S. miltiorrhiza extract combined with cyproterone acetate (CPA) and CPA alone in terms of decreasing TC (MD: –0.77, 95% CI: –0.89 to –0.65, P < 0.00001 ), TG (MD: –0.43, 95% CI: –0.65 to –0.20, P < 0.0001 ), and low-density lipoprotein cholesterol (MD: –0.49, 95% CI: –0.66 to –0.33, P < 0.00001 ) and increasing high-density lipoprotein cholesterol (MD: 0.30, 95% CI: 0.20, 0.40, P < 0.00001 ). In addition, S. miltiorrhiza extract also decreased testosterone, follicle-stimulating hormone, and luteinizing hormone. The studies did not mention any adverse events with S. miltiorrhiza extract. Conclusion. The current studies indicate that S. miltiorrhiza has beneficial effects on reproduction and glucose and lipid metabolism in patients with PCOS, and it is generally safe for clinical application. However, more prospective RCTs with large samples, multiple centers, and longer intervention duration are needed in the future to obtain more reliable conclusions.

show abstract

“…Polycystic ovary syndrome (PCOS) is known as the most common endocrine/metabolic disorder in women of reproductive age, where it is reported that PCOS affects 5 to 26 percent of women (based on the applied diagnostic criteria) around the world. 1 , 2 PCOS was found to be associated with different diseases such as metabolic syndrome, type 2 diabetes, hypertension, cardiovascular diseases and even ovulatory infertility. 3 , 4 There are four distinguished subtypes; inflammatory, hidden cause and finally, pill‐induced PCOS and insulin‐resistant (the most prevalent type).…”

Section: Introductionmentioning

confidence: 99%

microRNAs and long non‐coding RNAs as biomarkers for polycystic ovary syndrome

Tamaddon

Azimzadeh

Tavangar

2022

J Cellular Molecular Medi

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is known as the most common endocrine/metabolic disorder in women of reproductive age, where it is reported that PCOS affects 5 to 26 percent of women (based on the applied diagnostic criteria) around the world. 1,2 PCOS was found to be associated with different diseases such as metabolic syndrome, type 2 diabetes, hypertension, cardiovascular diseases and even ovulatory infertility. 3,4 There are four distinguished subtypes; inflammatory, hidden cause and finally, pill-induced PCOS and insulin-resistant (the most prevalent type). 5,6 Although the complete etiology of the syndrome remains unclear, the genetic, epigenetic, environmental factors and lifestyle have been associated with PCOS causality. In clinical and/or biochemical settings, diagnosis is based on whether the patient shows no less than two out of three main symptoms, including cysts in the ovaries, high androgen levels and irregular periods. Despite the controversial opinions of current diagnostic criteria of PCOS, an expert opinion from the ultrasound, pelvic exam and blood tests can confirm the diagnosis. 7,8 Blood tests for PCOS are mainly based on hormone levels and endocrine function,

show abstract

The role of androgen and its related signals in PCOS

Cited by 97 publications

References 108 publications

The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials

The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials

The Effects of Salvia miltiorrhiza on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

microRNAs and long non‐coding RNAs as biomarkers for polycystic ovary syndrome

Contact Info

Product

Resources

About